One of the most serious health threats facing Americans today is the malady designated as obesity. There are 500 million Adults, a whopping 31 percent of the population, who are not simply overweight; they are classified as unable to enjoy optimum health and activity because of their weight.
The health risks most commonly linked to obesity are heart attack, stroke, high blood pressure, high cholesterol, and diabetes. The annual medical costs associated with these ills are astronomical. The risk of health issues are high for those who are overweight, however, when one is obese, the chance of risk rises exponentially.
The good news is that pharmaceutical Company, Vivus, has an innovative new product that is designed to foster significant weight loss in obese patients. This product has recently announced approval for this medication named Qsymia, commonly termed as the weight loss pill.
The fact that the FDA is moving to approve a weight loss drug this year, is notably significant. The Food and drug administration has not approved a diet medication in the past decade. Qsymia is a combination drug. In other words, it is actually two separate drugs working together in one pill. Both drugs already have been known to enjoy success in the area of weight loss therapy.
The results from the Food and Drug Administration's clinical trials are more than convincing. The weight loss pill outperformed any other drugs that were also tested by the FDA. In one independent study; patients taking it for one year lost 6.7 percent of their body weight. In another study patients lost a reported 8.9 percent. In that same study, patients on the strongest dosage lost 11 percent of total body weight. To put it in pounds, patients reported losing as many as 22 pounds.
The two drugs that combine to make Qsymia are Phentermine and Topiramate. Phentermine is a stimulant and appetite suppressant, long acknowledged for its advantage for weight loss. Topiramate is an anti-consultant, which also makes people feel more satisfied after eating. Researchers have determined that the innovation of Qsymia is that it targets more than one component that causes people to overeat.
Research also reveals that Qsymia usage correlates to lower blood pressure and the easement of other cardiovascular risks associated with obesity. There is also reported improvement in the sleep disorder known as sleep apnea.
There are certain restrictions that are assigned to Qsymia by the FDA. For example, it is only approved for use in adults. It is also restricted to use only by patients who are diagnosed as clinically obese. In addition, pregnant women are prohibited from using it. This drug must be prescribed and monitored by a physician.
Physicians and clinics on the leading edge of practice have adapted their offerings to their patients based on the results of these studies. They see this as another tool to wage battle against obesity. One such company; Equilibrium Weight loss and Longevity offers Qsymia as part of a comprehensive line of weight loss protocols.
The health risks most commonly linked to obesity are heart attack, stroke, high blood pressure, high cholesterol, and diabetes. The annual medical costs associated with these ills are astronomical. The risk of health issues are high for those who are overweight, however, when one is obese, the chance of risk rises exponentially.
The good news is that pharmaceutical Company, Vivus, has an innovative new product that is designed to foster significant weight loss in obese patients. This product has recently announced approval for this medication named Qsymia, commonly termed as the weight loss pill.
The fact that the FDA is moving to approve a weight loss drug this year, is notably significant. The Food and drug administration has not approved a diet medication in the past decade. Qsymia is a combination drug. In other words, it is actually two separate drugs working together in one pill. Both drugs already have been known to enjoy success in the area of weight loss therapy.
The results from the Food and Drug Administration's clinical trials are more than convincing. The weight loss pill outperformed any other drugs that were also tested by the FDA. In one independent study; patients taking it for one year lost 6.7 percent of their body weight. In another study patients lost a reported 8.9 percent. In that same study, patients on the strongest dosage lost 11 percent of total body weight. To put it in pounds, patients reported losing as many as 22 pounds.
The two drugs that combine to make Qsymia are Phentermine and Topiramate. Phentermine is a stimulant and appetite suppressant, long acknowledged for its advantage for weight loss. Topiramate is an anti-consultant, which also makes people feel more satisfied after eating. Researchers have determined that the innovation of Qsymia is that it targets more than one component that causes people to overeat.
Research also reveals that Qsymia usage correlates to lower blood pressure and the easement of other cardiovascular risks associated with obesity. There is also reported improvement in the sleep disorder known as sleep apnea.
There are certain restrictions that are assigned to Qsymia by the FDA. For example, it is only approved for use in adults. It is also restricted to use only by patients who are diagnosed as clinically obese. In addition, pregnant women are prohibited from using it. This drug must be prescribed and monitored by a physician.
Physicians and clinics on the leading edge of practice have adapted their offerings to their patients based on the results of these studies. They see this as another tool to wage battle against obesity. One such company; Equilibrium Weight loss and Longevity offers Qsymia as part of a comprehensive line of weight loss protocols.
About the Author:
To learn if Qsymia Capsules are available around your location? Most people will need a doctors approval to get the Qsymia
0 commentaires:
Post a Comment